hotspot -WSS

hotspot

author：comprehensive 2025-10-02 09:47:08 - browse：9668

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

entertainment

WSS

Abortion pill case raises question: who can sue the FDA?

Families look for replacement for GSK asthma drug Flovent

Longer MASH drug regimen improved liver, Akero study finds

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Lack of health data on LGBTQ+ people has serious consequences

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

New air purifier tech could be key to improving indoor air quality

Merck drug for rare lung condition set for approval in U.S.

The high cost of giving birth even with insurance

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Medical leaders decry Supreme Court decision on affirmative action

Streamlined flu vaccines recommended by FDA advisory panel

DIEP, the 'gold standard' of breast reconstruction, is under threat

The public health thinking behind the CDC’s new Covid guidance

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why the world’s most expensive drug might be worth the price

hotspot

Readout Newsletter: Merck, Vertex, and Viking updates

Ozempic has benefits for kidney disease as well as diabetes

Streamlined flu vaccines recommended by FDA advisory panel

Longer MASH drug regimen improved liver, Akero study finds

Microsoft's Peter Lee: Generative AI could help doctors be more human

Oprah kicked off a national conversation on obesity. Let's have it

explore

focus

entertainment

focus